BBIO - BridgeBio Pharma, Inc.
| Previous Close | 34.99 |
| Open | 34.99 |
| Bid | 34.29 x 900 |
| Ask | 36.83 x 1100 |
| Day's Range | 34.31 - 36.14 |
| 52 Week Range | 17.61 - 48.36 |
| Volume | 266,461 |
| Avg. Volume | 406,348 |
| Market Cap | 4.466B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.73 |
| Earnings Date | Nov 06, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43.57 |
- GlobeNewswire
BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences
PALO ALTO, Calif., Feb. 21, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), together with affiliate company Eidos Therapeutics (Nasdaq: EIDX) announced today that they are.
- GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Feb. 05, 2020 -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on.
- GlobeNewswire
BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source
BridgeBio Pharma, Inc. (BBIO) today disclosed four additional assets in its pipeline, expanding the number of disclosed programs to over 20 potential medicines. BridgeBio’s world-class team of experienced drug developers are advancing these therapies with the aim of delivering life-changing medicines to patients. BridgeBio founder and CEO Neil Kumar, Ph.D., will discuss these new assets and BridgeBio’s pipeline during a presentation at the 38th Annual J.P. Morgan Healthcare Conference today at 3 PM (PST) in San Francisco.
- GlobeNewswire
BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity
BridgeBio Pharma, Inc. (BBIO) today announced a collaboration agreement with Catalent to establish dedicated gene therapy development and manufacturing capacity at Catalent’s Paragon Gene Therapy clinical and commercial manufacturing center in Harmans, Maryland. The agreement is intended to support the clinical and commercial manufacturing needs for BridgeBio’s gene therapy product candidates for congenital adrenal hyperplasia, BBP-631, and Canavan disease, BBP-812.
- Business Wire
PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma
PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq: BBIO) company, today announced it has dosed the first two participants in a Phase 2 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel for people with non-Gorlin High Frequency Basal Cell Carcinoma (HF-BCC). HF-BCC is a rare disease that causes a higher than average number of BCCs to develop, specifically in the facial area. PellePharm is a late clinical-stage biopharmaceutical company committed to targeting rare forms of basal cell carcinoma (BCC).
- GlobeNewswire
BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma
BridgeBio Pharma, Inc. (BBIO) subsidiary QED Therapeutics announced today that it has secured both Fast Track Designation in adults with first-line advanced or metastatic cholangiocarcinoma and Orphan Drug Designation for infigratinib for treatment of cholangiocarcinoma. In addition, the company announced that enrollment is ongoing and patient dosing has started in the PROOF trial, a Phase 3 clinical trial evaluating oral infigratinib, an investigational drug, in adults for first-line treatment of advanced cholangiocarcinoma with FGFR2 (fibroblast growth factor receptor 2) gene fusions or translocations.
- GlobeNewswire
BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference
PALO ALTO, Calif., Dec. 19, 2019 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday,.
- GlobeNewswire
BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A
BridgeBio Pharma, Inc. (BBIO) subsidiary Origin Biosciences, a company focused on developing and commercializing a treatment for Molybdenum Cofactor Deficiency (MoCD) Type A, and Medison Pharma Ltd., a leading commercial biotech partner that operates in Israel, Canada and Central and Eastern European countries, have entered into an exclusive license agreement under which Medison received rights from Origin to distribute, market, sell and otherwise commercialize Origin’s drug product known as fosdenopterin (BBP-870/ORGN001) in Israel.
- GlobeNewswire
BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member
BridgeBio Pharma, Inc. (BBIO) today announced it has appointed Jennifer Cook to its Board of Directors and will leverage her considerable expertise as a special advisor to the senior management team. “Jennifer is a seasoned leader in the biotech and pharmaceutical spaces, with decades of experience taking drugs from research to commercialization,” said Richard Scheller, Ph.D., chairman of research and development at BridgeBio.
- Insider Monkey
BridgeBio Pharma, Inc. (BBIO): Are Hedge Funds Right About This Stock?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
- Benzinga
The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
- GlobeNewswire
BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs
BridgeBio Pharma, Inc. (BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced it has appointed Eli Wallace, Ph.D., as its chief scientific officer in residence for oncology effective immediately. In this new role, Dr. Wallace will oversee BridgeBio’s ongoing discovery efforts in targeted oncology while driving the identification and adoption of new oncology programs. “Eli is a brilliant medicinal chemist with an outstanding record of accomplishment in drug development at Array BioPharma and Peloton Therapeutics,” said Frank McCormick, Ph.D., chairman of oncology at BridgeBio.
- GlobeNewswire
BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A
BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences has initiated a rolling submission of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for fosdenopterin (BBP-870/ORGN001) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. Currently, there are no approved therapies that alter the course of MoCD Type A, which results in severe and irreversible neurological injury. Fosdenopterin, an investigative cPMP substrate replacement therapy, aims to reduce buildup of toxic sulfites and alleviate central nervous system symptoms in infants and children with MoCD Type A.
- GlobeNewswire
CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
Correction updates the increase in mean serum TTR levels for variant-carrying ATTR-CM to 56% at OLE Visiting Day 180. BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO) and Eidos Therapeutics, Inc. (Eidos) (EIDX), today presented positive data from the companies’ ongoing Open Label Extension (OLE) of the Phase 2 clinical trial studying AG10 in patients with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM).
- GlobeNewswire
BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO) and Eidos Therapeutics, Inc. (Eidos) (EIDX), today presented positive data from the companies’ ongoing Open Label Extension (OLE) of the Phase 2 clinical trial studying AG10 in patients with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM). ATTR-CM is a progressive and fatal disease that is an under recognized cause of heart failure.
- GlobeNewswire
BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress
Multiple clinical and pre-clinical milestones achieved across the BridgeBio portfolioDelivered pipeline growth with the addition of BBP-418 for limb-girdle muscular dystrophy.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On BridgeBio Pharma, Inc. (BBIO)
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
- PR Newswire
BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential in Two Rare Disease Indications at the European Society of Gene and Cell Therapy Conference
SAN FRANCISCO, Oct. 22, 2019 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced that promising preclinical data from two of its gene therapy-focused subsidiaries – Adrenas Therapeutics and Aspa Therapeutics – will be presented at the European Society of Gene and Cell Therapy (ESGCT) Conference, occurring in Barcelona from October 22 to 25. In addition, the company announced that Aspa Therapeutics is currently conducting a natural history study in children with Canavan disease, CANinform.
- PR Newswire
QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia
SAN FRANCISCO, Oct. 17, 2019 /PRNewswire/ -- QED Therapeutics, Inc. and parent company BridgeBio Pharma, Inc. (NASDAQ: BBIO) announced today the presentation of preclinical data supporting the potential of low-dose infigratinib for the treatment of achondroplasia. Achondroplasia is the most common cause of dwarfism and is caused by mutation of the gene for fibroblast growth factor receptor 3 (FGFR3).
- GlobeNewswire
Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options
The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma, Inc., (Nasdaq:BBIO) to investigate the FGFR1-3 tyrosine kinase inhibitor, infigratinib, for the treatment of glioblastoma (GBM). With the goal of addressing unmet medical needs for those affected by malignant brain cancer, this collaboration will focus on targeting FGFR (fibroblast growth factor receptor) genetic alterations that have been shown to spur growth in malignant tumors.
- GlobeNewswire
BridgeBio Pharma’s Origin Biosciences Presents New Data on the Natural History of Molybdenum Cofactor Deficiency (MoCD) Type A at the Society of the Study of Inborn Errors of Metabolism (SSIEM) Conference
BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences announced today the presentation of a study on the natural history of patients with Molybdenum Cofactor Deficiency (MoCD) and isolated sulfite oxidase deficiency (ISOD).
